Joris Holtrop

Joris Holtrop

Auto-generated profile, based on publicly available information

Joris Holtrop

Department of Vascular Medicine and Endocrinology, University Medical Centre Utrecht , Utrecht

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in Atherosclerosis
Verified
Journal Article
Open access
PBPascal M. Burger
Pascal M. Burger
JDJannick A.N. Dorresteijn
Jannick A.N. Dorresteijn
SKStefan Koudstaal
Stefan Koudstaal
JHJoris Holtrop
Joris Holtrop
JKJohn J.P. Kastelein
John J.P. Kastelein
FVFrank L.J. Visseren
Frank L.J. Visseren
Individuals with or at high risk of cardiovascular disease (CVD) often receive long-term treatment with low-density lipoprotein cholesterol (LDL-C) lowering therapies, but whether the effects of LDL-C reduction remain stable over time is uncertain. This study aimed to establish the course of the effects of LDL-C reduction on cardiovascular risk over time. Randomized controlled trials (RCTs) of LDL-C lowering therapies were identified through a search in MEDLINE and EMBASE (1966-January 2023). The primary analyses were restricted to statins, ezetimibe, and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, with other therapies included in sensitivity analyses. Random-effects meta-analyses were performed to establish the hazard ratio (HR) for major vascular events (cardiovascular death, myocardial infarction, unstable angina, coronary revascularization, or stroke) per 1 mmol/L LDL-C reduction. Course of the effects over time was assessed using random-effects meta-regression analyses for the association between follow-up duration, age, and the HR for major vascular events per 1 mmol/L LDL-C reduction. Additionally, treatment-by-time interactions were evaluated in an individual participant data meta-analysis of six atorvastatin trials. A total of 60 RCTs were identified (408,959 participants, 51,425 major vascular events). The HR for major vascular events per 1 mmol/L LDL-C reduction was 0.78 (95 % confidence interval [CI] 0.75-0.81). Follow-up duration was not associated with a change in the HR for major vascular events (HR for change per year 0.994; 95 % CI 0.970-1.020; p = 0.66). The HR attenuated with increasing age in primary prevention (HR for change per 5 years 1.097; 95 % CI 1.031-1.168; p = 0.003), but not secondary prevention (HR for change per 5 years 0.987; 95 % CI 0.936-1.040; p = 0.63). Consistent results were found for statin trials only, and all trials combined. In the individual participant data meta-analysis (31,310 participants, 6734 major vascular events), the HR for major vascular events did not significantly change over follow-up time (HR for change per year 0.983; 95 % CI 0.943-1.025; p = 0.42), or age (HR for change per 5 years 1.022; 95 % CI 0.990-1.055; p = 0.18). Based on available RCT data with limited follow-up duration, the relative treatment effects of LDL-C reduction are stable over time in secondary prevention, but may attenuate with higher age in primary prevention.

7 February 2024 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
JHJoris Holtrop
Joris Holtrop
DBDeepak L Bhatt
Deepak L Bhatt
KRKausik K Ray
Kausik K Ray
FMFrançois Mach
François Mach
YSYvo M Smulders
Yvo M Smulders
JDJannick A N Dorresteijn
Jannick A N Dorresteijn
Aims: This study aimed to evaluate the stepwise approach for cardiovascular (CV) risk factor treatment as outlined by the European Society for Cardiology 2021 guidelines on CV disease (CVD) prevention in patients with established atherosclerotic CVD (ASCVD). Methods and results: In patients with ASCVD, included in UCC-SMART (n = 8730) and European parts of the REACH registry (n = 18 364), the 10-year CV risk was estimated using SMART2. Treatment effects were derived from meta-analyses and trials. Step 1 recommendations were LDL cholesterol (LDLc) < 1.8 mmol/L, systolic blood pressure (SBP) < 140 mmHg, using any antithrombotic medication, sodium–glucose co-transporter 2 (SGLT2) inhibition, and smoking cessation. Step 2 recommendations were LDLc < 1.4 mmol/L, SBP < 130 mmHg, dual-pathway inhibition (DPI, aspirin plus low-dose rivaroxaban), colchicine, glucagon-like peptide (GLP)-1 receptor agonists, and eicosapentaenoic acid. Step 2 was modelled accounting for Step 1 non-attainment. With current treatment, residual CV risk was 22%, 32%, and 60% in the low, moderate, and pooled (very) high European risk regions, respectively. Step 2 could prevent up to 198, 223 and 245 events per 1000 patients treated, respectively. Intensified LDLc reduction, colchicine, and DPI could be applied to most patients, preventing up to 57, 74, and 59 events per 1000 patients treated, respectively. Following Step 2, the number of patients with a CV risk of <10% could increase from 20%, 6.4%, and 0.5%, following Step 1, to 63%, 48%, and 12%, in the respective risk regions. Conclusion: With current treatment, residual CV risk in patients with ASCVD remains high across all European risk regions. The intensified Step 2 treatment options result in marked further reduction of residual CV risk in patients with established ASCVD. Key findings: Guideline-recommended intensive treatment of patients with cardiovascular disease could prevent additional 198–245 new cardiovascular events for every 1000 patients treated.

10 October 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
SHSteven H J Hageman
Steven H J Hageman
SKStephen Kaptoge
Stephen Kaptoge
MGMari N Gynnild
Mari N Gynnild
JHJoris Holtrop
Joris Holtrop
LPLisa Pennells
Lisa Pennells
FVFrank L J Visseren
Frank L J Visseren
Aims: Current European Cardiovascular Disease (CVD) prevention guidelines recommend 10-year risk assessment using the SCORE2 model to identify individuals eligible for preventive treatment. Risk can be estimated using conventional risk charts or online calculators, though these methods may differ in precision and treatment classification. Methods and results: Individuals without established CVD or diabetes mellitus were included from CPRD (UK, Europe’s low risk region, n = 977 616) and HAPIEE (Czech Republic and Poland, high risk region and Lithuania, very high risk region, n = 11 739). During median 8.4 years [interquartile range (IQR) 5.0–10.4], 22 898 CVD events occurred. SCORE2 risk was estimated via two methods: an online calculator (unrounded SCORE2 algorithm) and risk charts from the 2021 ESC Prevention Guidelines. Predicted risks were higher with the risk charts than with the online calculator. In the low risk region, the median 10-year risk was 4.0% (IQR 2.0–6.0) with the risk charts vs. 3.7% (IQR 2.3–5.8) with the calculator. In the high/very high-risk region, risk was 9.0% (IQR 5.0–15.0) and 8.4% (IQR 4.5–13.9), respectively. Chart-based risk assessment resulted in higher treatment eligibility (6.3% vs. 4.0% in the low risk region; 51% vs. 43% in high/very high risk region). Discrimination was higher with the online calculator: difference in C-statistic +0.010 [95% confidence interval (CI) 0.008–0.012] in low risk region and +0.008 (95% CI 0.005–0.010) in high/very high risk region. Calibration was adequate for both approaches. Assuming a 50% relative risk reduction for preventive treatment, this corresponded to 53 vs. 46 events prevented per 1000 treated in the low-risk region and 80 vs. 74 in the high/very-high-risk region (calculator vs. risk charts). Conclusion: Risk assessment using SCORE2 risk charts yields too high predicted risks and too broad treatment eligibility. By avoiding rounding of risk factors, the online calculator shows better discrimination.

11 March 2026 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TRTessa H Reitsma
Tessa H Reitsma
GSGianluigi Savarese
Gianluigi Savarese
ŁKŁukasz Kuźma
Łukasz Kuźma
SDSalil V Deo
Salil V Deo
LPLisa Pennells
Lisa Pennells
MKMaryam Kavousi
Maryam Kavousi
Background and Aims: Heart failure (HF) with preserved ejection fraction (HFpEF) constitutes a heterogeneous disease with varying prognosis. Given the rising incidence of HFpEF, accurate risk prediction for these patients is needed to identify high-risk individuals, who may benefit the most from preventive treatments. The LIFE-Preserved model was developed and validated for the prediction of individual short-term and lifetime risk for HF hospitalization or cardiovascular (CV) death in patients with HFpEF. Methods: LIFE-Preserved was derived in 20 332 patients aged 40–90 years with a left ventricular ejection fraction ≥ 50% from the Swedish HF Registry. Cause- and sex-specific Cox models were derived to predict the risk of HF hospitalization or CV death using 14 routinely available predictors. Use of age as the timescale allowed for predictions beyond the maximum follow-up duration in the derivation data, adjusted for competing risks. External validation was performed in two trials (EMPEROR-Preserved and TOPCAT-Americas) and three registries (NHS England Secure Data Environment, Veterans Affairs, and HF-Particles). Model performance was assessed by discrimination and calibration. Results: During a median follow-up of 1.8 years (interquartile range .6–4.2, maximum 19 years), 9341 first HF hospitalizations or CV deaths (46%) were observed in Swedish HF Registry. External validation included data from 28 062 patients with HFpEF [9930 (35%) first HF hospitalizations or CV deaths]. Pooled C-statistics were .714 (95% confidence interval .652–.775) in trials and .658 (95% confidence interval .599–.717 in registries, with adequate calibration in all external validation sources. Performance was similar in men and women. An interactive calculator of the LIFE-Preserved model has been made available here. Conclusions: The LIFE-Preserved model enables prediction of short-term and lifetime risk of HF hospitalization or CV death in patients with HFpEF. The model could serve as a tool to identify high-risk HFpEF patients, guiding clinical management and shared decision-making.

11 March 2026 in European Heart Journal
Verified
Journal Article
Open access
TRTessa H Reitsma
Tessa H Reitsma
CLCarl-Emil Lim
Carl-Emil Lim
MGMari N Gynnild
Mari N Gynnild
SKStephen Kaptoge
Stephen Kaptoge
LLLaura Lõo
Laura Lõo
FVF L J Visseren
F L J Visseren
Background and Aims: Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of developing heart failure (HF). However, incident HF is not part of the risk assessment of current guideline-recommended models. The aim of this study was to develop and externally validate the SMART2-HF model for prediction of incident HF in patients with ASCVD. Methods: SMART2-HF was developed in 7698 individuals with established ASCVD (coronary, cerebrovascular, or peripheral artery disease, or abdominal aortic aneurysm) but without prior HF from the UCC-SMART cohort. Cox proportional hazards models including sex-predictor interactions and with age as the time scale were derived to estimate the 10-year and lifetime risk of incident HF (hospitalization for HF or HF-related death), accounting for competing non-HF mortality. Predictors, limited to routinely available clinical characteristics, were aligned with the SMART2 risk model for recurrent cardiovascular (CV) risk in the same population. External validation was performed in 240 741 patients with ASCVD from six data sources: the Clinical Practice Research Datalink, the HUNT3 study, the SWEDEHEART Registry, the ASCVD-Particles cohort, the Estonian Biobank and the international REACH Registry. Results: During a median follow-up of 11.2 years (interquartile range 6.1–16.4 years), 1031 incident HF events (13%) occurred in the UCC-SMART cohort. In the external validation data sources, a total of 24 885 incident HF events (10%) occurred. The pooled C-statistic was .696 (95% confidence interval .674–.717), with consistent performance in subgroups by sex and type of ASCVD. Predicted risks matched observed incidence in external validation. Conclusions: The SMART2-HF model enables the prediction of incident HF in patients with ASCVD. Aligned with the guideline-recommended SMART2 model for recurrent CV risk, SMART2-HF can be used as a complementary tool in this population.

23 June 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
MGMari Nordbø Gynnild
Mari Nordbø Gynnild
JHJoris Holtrop
Joris Holtrop
SHSteven H J Hageman
Steven H J Hageman
VVVictoria Vinje
Victoria Vinje
JDJannick A N Dorresteijn
Jannick A N Dorresteijn
TOTorbjørn Omland
Torbjørn Omland
Aims: The 2022 European Society of Cardiology cardio-oncology guidelines recommend cardiovascular disease (CVD) risk stratification for cancer patients and suggest using SCORE2 and SCORE2-OP. However, these models have not been validated or specifically adapted for cancer populations. Our aim was to refine the SCORE2 and SCORE2-OP models to accurately predict 10-year fatal and non-fatal CVD risk in cancer patients. Methods and results: We included 1622 patients from the HUNT3 study (2006–08) who were diagnosed with cancer within 4 years after their enrolment and followed until 2023 linked to national registries. The primary outcome was a composite of myocardial infarction (MI), stroke, or CVD mortality. Model performance was assessed using Harrel’s C-statistic and calibration curves. Both models were recalibrated by applying a multiplicative adjustment factor based on expected–observed (E/O) ratios. The most prevalent cancers were gastrointestinal (23%), prostate (17%), and breast (14%). Mean age was 65.2 years, 52% were female. During a median follow-up of 8.8 years [inter-quartile range 1.9–12.6], 252 CVD events (39% MI, 36% stroke, 25% CVD deaths) and 708 non-CVD deaths occurred. SCORE2 initially underestimated CVD risk (E/O ratio for men and women: 0.91 and 0.63, respectively) but showed adequate agreement after recalibration. C-statistics for SCORE2 was 0.693 [95% confidence interval (CI) 0.643–0.743], and 0.730 (95% CI 0.676–0.784) after excluding those not surviving the first 2 years. For SCORE2-OP, the C-statistics were 0.586 (95% CI 0.529–0.643) and 0.648 (95% CI 0.577–0.720). Conclusion: SCORE2 underestimated CVD risk in cancer patients. After recalibration, the model may serve as a valuable tool for risk stratification in cancer patients.